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cense (Connecting science past and futureI recently read the article on protein A pretreatment, allevia-
tion of inflammatory reaction, and evaluation of biosafety in vivo
in the March 2016 edition of the Journal of the Chinese Medical
Association.1 I applaud the renewed research on Staphylococcus
aureus protein A (SPA), and would refer to the very pertinent
previously published information on SPA efficacy and toxicity.
While SPA in rats and mice does not bind a complement fixing
class of antibody and is safe at greater doses, this is not the case in
guinea pigs and humans. SPA at a dose of 1 mg/kg can cause a
lethal anaphylactoid reaction in guinea pigs and possibly in
humans.2,3 U.S. Patent No. 5,189,014 (Cowan) describes using
Fc receptor (FcR) to treat diverse pathologies having an FcR-
mediated immune component, including bacterial and viral
infections, autoimmune disorders, transplant rejection, and
cancer.3 The patent and citations show SPA toxicity is a concern
but manageable and demonstrate the reduced toxicity of mono-
valent SPA (MSPA) fragments having only a single Fc antibody
binding site. This patent and information derived from earlier
studies and their related publications helped to pioneer the field
of receptors as drugs and establish the role of FcRs as effectors of
immune regulation that can influence gene expression, cellular
differentiation, viral replication, and malignant transformation.4
The field of FcR-based drugs remains a focus of contemporary
science long after the original discovery.5
Previous work on FcR immunotherapy suggested a broad
range of immune regulatory effects on endogenous FcR-
mediated immunity, and potential therapeutic effects in many
diseases with associated abnormal FcR-mediated immunity.3,4
For example, the early work by Coley showed antineoplastic
activity of bacterial extracts likely to have contained FcR-like
proteins.6 Interestingly, sera perfused through SPA columns
were observed to have antineoplastic activity in animal models
and human patients, but the antineoplastic action of the perfused
serawas lost as the SPA column technology improved to provide
better binding of SPA to the support matrix and less leaching of
SPA.7 Systemic injection of SPA in animal models also pro-
duced antineoplastic results.3,4,8However, tomyknowledge, the
concept of systemic SPAeFcR immunotherapy with known
injected doses was never tested clinically in human patients. At
the time of our early publications, only SPAeFcR activity was
known and proposed as the best mode of action.3 Other binding
actions of SPA such as Fab antibody “superantigen” are now
known. Many of the broad observations we made could bex.doi.org/10.1016/j.jcma.2016.09.003
901/Copyright © 2016, the Chinese Medical Association. Published by Else
http://creativecommons.org/licenses/by-nc-nd/4.0/).caused by or influenced synergistically by binding mechanisms
other than SPAeFcR. SPA deserves new study that brings
together past discovery and modern technology. Exciting pro-
gress in this direction has been made by Protalex, Inc., which is
developing immunotherapies using MSPA to treat pathological
inflammatory responses and autoimmune diseases.9
Much of the current drug development science and technol-
ogy remains narrowly focused on single sites of drug action,
even as we apply vastly increased volumes and complexities of
data from arrays, algorithms, and analyses of genes and mole-
cules. The focus on single sites of action ignores biological
redundancy and the multiple pharmacological actions of many
drugs and molecules, SPA included. Complexity can sometimes
defeat purpose and hide a simple, straightforward, and cost-
effective insight for efficacy. Modern medical drug discovery
has its roots in traditional medicine that lacked mechanistic
knowledge but was fully aware of its efficacy. A better marriage
of modern and traditional medicine might better link efficacy to
information and collectively provide avenues to more beneficial
therapies, and ultimately yield a deeper understanding of the
relationship of biological processes underlying efficacy.
FcR-mediated immunity and inflammation occur in most
injuries, insults, and diseases. Serious harm can result when
inflammatory responses become pathological. The multithreat
medical countermeasure (MTMC) hypothesis proposes that
pathological inflammatory responses are a major common
mediator in the pathology of many damaging chemical insults,
and similar mediators, mechanisms, pathways, and cell pro-
cesses are associated with trauma, cancer, and a multitude of
other diseases.9 Known anti-inflammatory drugs and other
drugs with secondary anti-inflammatory pharmacology can be
used in combinations that act synergistically to provide ther-
apeutic effects.9,10 Furthermore, the physiological to pharma-
cological spectrum of diet, dietary supplements, traditional
medicines and herbs, and drugs can be used singly or in
synergistic combinations to alter inflammatory response and
provide new pathways to therapeutic treatments.10 In this
respect, biomarkers are a cornerstone of MTMC development,
as they allow measuring and evaluating relevant “situational”
immunity such as hypercytokinemia that may be critical to
both health and pathology, and efficacy and toxicity.
Mechanistically, the “cytokine storm” (hypercytokinemia) is
associated with soluble mediators, receptoreligand binding,vier Taiwan LLC. This is an open access article under the CC BY-NC-ND li-
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and a host of cellecell interactions that influence inflamma-
tion and related cellular processes such as apoptosis, and pro-
vides some commonality of mechanism for a variety of
pathologies.9,10e12 Inflammatory pathologymay be as varied as a
potentially acutely lethal systemic reaction, an arthritic joint, a
cutaneous blister caused by the chemical warfare agent sulfur
mustard, or neuronal damage associated with trauma, or Alz-
heimer's disease. The potential of pharmaceutical approaches in
treating hypercytokinemia-induced pathology is limited by the
lack of anti-inflammatory drugs that effectively influence these
harmful immune responses. Applying MTMC concepts to iden-
tify combinations of drugs and compounds that synergistically
inhibit hypercytokinemia by systematically screening levels of
key biomarkers of inflammation may help overcome this limi-
tation.9,10 Such biomarkers include genetic components, cell
populations, cellular processes such as apoptosis, proin-
flammatory cytokines [e.g., interleukin-6 (IL-6), IL-8], anti-
inflammatory cytokines (e.g., IL-10), and more generalized bio-
markers of inflammation such as complement-reactive protein.
One of the articles I have encountered that best merges his-
torical reflection and modern perspective is by Coventry and
Ashdown.13They point out that the incidence of complete clinical
responses for most metastatic cancers has remained constant and
low between 5% and 10% for many decades, and that this same
constant, low rate of success holds for all treatment modal-
itiesdchemotherapy, radiation, surgery, or other means. They
suggest that “Inflammatory and immune responses appear intri-
cately associated with, if not causative of, complete responses
induced by divergent forms of cancer therapy…leaving inflam-
mation and immune system stimulation as a final common
denominator across all of thesemechanisms of cancer therapy.” If
such immune mechanisms and biorhythm cycles were coupled
with anti-inflammatoryMTMC to reduce hypercytokinemia, one
wonders how this might affect clinical responses for metastatic
cancers and perhaps many other pathologies and diseases.
The process of discovery has a vital role in harmonizing
traditional andmodernmedicine, efficacy, and information. The
failure of modern science to connect with its history causes
inaccuracy and breaks the continuity of ideas. This also yields
false accreditation of discoveries and can weaken or destroy
patent intellectual property. A chief culprit is the vast scope of
scientific information. Technology moves fast, rendering any-
thing not published within the last half decade often unread,
uncited, and unknown. Time to read and reflect on published
scientific literature, including patents, is a scarce luxury that
most contemporary scientists do not have in their “produce or
perish” enterprise that generates even more new information.
Scientists value and rely on the record of discovery, but over-
sights and errors in citation are readily replicated in the scientific
literature without much notice or correction. This can prevent
the broader distribution of valuable insights and information,
cause duplication of effort, and retard progress in science.
Harmonizing the record of discovery in the marriage of tradi-
tional medicine and modern science would promote new
insights and discoveries in medicine and science.Conflicts of interest
The author declares that he has no conflicts of interest related
to the subject matter or materials discussed in this article.Acknowledgments
This paper was reviewed and edited by Charles C. P.
Rories, PhD (Ph.D. in Biochemistry and Nutrition, University
of North Carolina, Chapel Hill, NC, 1986).References
1. Wang D, Liu Y, Zhao Y, Zhou J. Low dose of protein A pretreatment can
alleviate the inflammatory reaction and the bio-safety was evaluated
in vivo. J Chin Med Assoc 2016;79:400e8.
2. Gustafson GT, Stålenheim G, Forsgren A, Sj€oquist J. “Protein A”
from Staphylococcus aureus. IV. Production of anaphylaxis-like cuta-
neous and systemic reactions in non-immunized guinea-pigs. J Immunol
1968;100:530e4.
3. Cowan FM. A method for treating cellular Fc receptor mediated immune
disorders. U.S. Patent No. 5,189,014, issued February 23, 1993, with
priority date December 3, 1979. (Col. 23, Example 6: MSPA and SPA
anaphylactoid reactions). Available from: https://www.google.com/
patents/US5189014 [Last accessed September 18, 2016].
4. Cowan FM, Klein DL, Armstrong GR, Stylos WA, Pearson JW. Fc
receptor mediated immune regulation and gene expression. Biomedicine
1980;32:108e10.
5. Hogarth PM, Pietersz GA. Fc receptor-targeted therapies for the treat-
ment of inflammation, cancer and beyond. Nat Rev Drug Discov
2012;11:311e31.
6. Wiemann B, Starnes CO. Coley's toxins, tumor necrosis factor and cancer
research: a historical perspective. Pharmacol Ther 1994;64:529e64.
7. Cowan FM. Staphylococcus aureus protein A immunoadsorption. The
rationale for systemic protein A immunotherapy. Toxicol Methods
1997;7:9e15.
8. Mann P. Protein A compositions and methods of use. Patent No. 7,211,258
B2, issued May 1, 2007. Available from http://www.google.co.in/patents/
WO2003086317A2?cl¼en [Last accessed September 18, 2016].
9. Cowan FM, Broomfield CA, Stojiljkovic MP, Smith WJ. A review of
multi-threat medical countermeasures against chemical warfare and ter-
rorism. Mil Med 2004;169:850e5.
10. Cowan FM. Phytochemical combinations that regulate pathological
immunity. U.S. Patent Application Publication No. 20110305779 A1,
published December 15, 2011, with priority date June 10, 2010. p. 1e2.
Available from: https://www.google.com/patents/US20110305779 [Last
accessed September 18, 2016].
11. Tisoncik JR, Korth MJ, Simmons CP, Farrar J, Martin TR, Katze MG. Into
the eye of the cytokine storm. Microbiol Mol Biol Rev 2012;76:16e32.
12. Waugh DJ, Wilson C. The interleukin-8 pathway in cancer. Clin Cancer
Res 2008;14:6735e41.
13. Coventry BJ, Ashdown ML. Complete clinical responses to cancer ther-
apy caused by multiple divergent approaches: a repeating theme lost in
translation. Cancer Manag Res 2012;4:137e49.
Fred M. Cowan*
Uppsala Inc., Colora, MD, USA
*Corresponding author. Fred M. Cowan, Uppsala Inc., 67
Shady Brook Drive, Colora, MD 21917, USA.
E-mail address: fred.cowan@zoominternet.net.
